L
Lisa K. Brents
Researcher at University of Arkansas for Medical Sciences
Publications - 29
Citations - 1321
Lisa K. Brents is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Medicine & Cannabinoid. The author has an hindex of 15, co-authored 22 publications receiving 1174 citations. Previous affiliations of Lisa K. Brents include Arkansas State University.
Papers
More filters
Journal ArticleDOI
Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
Lisa K. Brents,Emily E. Reichard,Sarah M. Zimmerman,Jeffery H. Moran,William E. Fantegrossi,Paul L. Prather +5 more
TL;DR: This study proposes that K2's high adverse effect occurrence is due, at least in part, to distinct JWH-018 metabolite activity at the cannabinoid 1 receptor (CB1R), and suggests that metabolites of most drugs, but not the carboxy metabolite, retain in vitro and in vivo activity at CB1Rs.
Journal ArticleDOI
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
Krishna C. Chimalakonda,Kathryn A. Seely,Stacie M. Bratton,Lisa K. Brents,Cindy L. Moran,Gregory W. Endres,Laura P. James,Paul F. Hollenberg,Paul L. Prather,Anna Radominska-Pandya,Jeffery H. Moran +10 more
TL;DR: Test the hypothesis that JWH-018 and its fluorinated counterpart AM2201 are subject to cytochrome P450 (P450)-mediated oxidation, forming potent hydroxylated metabolites that retain significant affinity and activity at the cannabinoid 1 (CB1) receptor.
Journal ArticleDOI
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
Lisa K. Brents,Anna Gallus-Zawada,Anna Radominska-Pandya,Tamara Vasiljevik,Thomas E. Prisinzano,William E. Fantegrossi,Jeffery H. Moran,Paul L. Prather +7 more
TL;DR: The present study indicates that further work examining the physiological effects of synthetic cannabinoid metabolism is warranted, and suggests that a complex mix of metabolically produced CB1R ligands may contribute to the adverse effect profile of JWH-073-containing products.
Journal ArticleDOI
The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products
Lisa K. Brents,Paul L. Prather +1 more
TL;DR: This review comprehensively describes the emergence of SCB abuse and provides a historical account of the major case reports, legal decisions and scientific discoveries of the “K2/Spice Phenomenon”.
Journal ArticleDOI
AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies
Kathryn A. Seely,Lisa K. Brents,Lirit N. Franks,Maheswari Rajasekaran,Sarah M. Zimmerman,William E. Fantegrossi,Paul L. Prather +6 more
TL;DR: In addition to high CB1R affinity, AM-251 and rimonabant bind to MORs with mid-nanomolar affinity and at higher doses may affect morphine analgesia via direct antagonism at MORs.